Mortality and major adverse cardiovascular events after transcatheter aortic valve replacement using Edwards valve versus CoreValve: A meta-analysis

Panchal, Hemang B.; Barry, Neil; Bhatheja, Samit; Albalbissi, Kais; Mukherjee, Debabrata; Paul, Timir K.

doi:10.1016/j.carrev.2015.11.005

Cited by 12 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result is consistent to a prior large multi-center study comparing ESV and Medtronic CoreValve (MCV) (Sapien 96.6% vs. MCV 95.6%) (17). In a meta-analysis by Panchal et al (18), they also reported similar device success rate between the two devices. However, in the randomized controlled CHOICE study (19), they reported that MCV had a lesser procedural success rate compared to Sapien XT (MCV 77.5% vs. Sapien XT 95.9%; P<0.001), which was likely due to the lower rates of severe PVL assessed using angiography with the Sapien XT compared to MCV.…”

Section: Discussionmentioning

confidence: 79%

Comparison of third generation balloon-expandable Edwards Sapien 3 versus self-expandable Evolut R in transcatheter aortic valve implantation: a meta-analysis

Tsauo

Liao

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

Background: The 3 rd generations of transcatheter heart valve system, including Edwards SAPIEN S3 (ES3) and Medtronic's Evolut R, has been developed to specifically improve the safety of transcatheter aortic valve implantation (TAVI). The aim of this work was to provide a summary effect estimate of the peri-procedural characteristics and clinical outcome of patients treated with ES3 versus the Evolut R.Methods: We conducted a literature search of PubMed, Ovid and EMBASE (2002 to 2018). Two authors extracted the data independently. The safety and feasibility of Sapien 3 and Evolut R were compared by odds ratios (ORs) with 95% confidence intervals (CIs) in inverse variance method.Results: After a multi-step assessment, a total 6 studies were finally included, yielding 1,664 patients, of which, 768 (46%) used ES3 and 896 (54%) used Evolut R. There was no statistical difference with device success rate (OR 1.15, 95% CI: 0.70-1.91, I 2 =0%), 30-day mortality [OR: 0.72 (0.33-1.57), I 2 =0%], pre-dilation rate, 30-day stroke, bleeding complication (BC) (major and life-threating), major vascular complication (VC), and paravalvular leakage between the two groups. However, the ES3 group was associated with a higher risk of acute kidney injury (AKI), higher mean aortic valve gradient and better mean left ventricular ejection fraction (LVEF) after TAVR procedure. Moreover, the Evolut R group had a higher rate of post-dilation and new permanent pacemaker implantation (PPMI).Conclusions: Both devices had demonstrated excellent procedural success rate and short-term safety. At 30-day follow-up, both devices shared similar rates of mortality, BC, VC, stroke, and paravalvular leakage (PVL). However, the rate of AKI was higher in the ES3 group, and the rate of PPM was higher in the Evolut R group.

show abstract

Section: Discussionmentioning

confidence: 79%

Comparison of third generation balloon-expandable Edwards Sapien 3 versus self-expandable Evolut R in transcatheter aortic valve implantation: a meta-analysis

Tsauo

Liao

et al. 2020

Ann Palliat Med

View full text Add to dashboard Cite

show abstract

“…Major vascular complications, bleeding, and stroke rates were comparable, as were 30‐day outcomes. A multicenter randomized trial comparing earlier generation BEV versus SEV reported significant differences in the rate of paravalvular leak and permanent pacemaker implantation, as well as valve hemodynamics, but no difference in mortality, findings that were confirmed in larger meta‐analyses . In contrast, there is a paucity of comparative data regarding contemporary third generation TAVR devices.…”

Section: Discussionmentioning

confidence: 99%

“…A multicenter randomized trial comparing earlier generation BEV versus SEV reported significant differences in the rate of paravalvular leak and permanent pacemaker implantation, as well as valve hemodynamics, but no difference in mortality, 12 findings that were confirmed in larger meta-analyses. 13,14 In contrast, there is a paucity of comparative data regarding contemporary third generation TAVR devices. In the first comprehensive report by Kodali et al of TAVR in high risk and inoperable patients using the Edwards Sapien 3 BEV, 30-day mortality was 2.2%, rate of major or disabling stroke was 0.9%, rate of moderate or severe paravalvular regurgitation was 3.7%, and permanent pacemaker implantation rate was 13.3%.…”

Section: Discussionmentioning

confidence: 99%

Contemporary transcatheter aortic valve replacement with third‐generation balloon‐expandable versus self‐expanding devices

Rogers

Steinvil

Buchanan

et al. 2017

J Interven Cardiology

View full text Add to dashboard Cite

show abstract

“…However, new-onset LBBB occurs much more frequently after TAVR, with reported rates ranging from 4% to 60% in the first generation THV systems (73). Similar to PPM, the incidence of new LBBB varies with the THV platform used and was lower in the early-generation, balloon-expandable SAPIEN valves (~10% to 25%) than the self-expanding CoreValve (~20% to 50%) (7,32,73,85,86). The incidence of new LBBB with the first-generation, mechanicallyexpandable Lotus valve was even higher, ranging from 50% to over 75% (87,88).…”

Section: Incidencementioning

confidence: 99%

The incidence and impact of cardiac conduction disturbances after transcatheter aortic valve replacement

Chen¹,

Chau²,

Nazif³

2020

Ann Cardiothorac Surg

View full text Add to dashboard Cite

Transcatheter aortic valve replacement (TAVR) has developed into an established therapy for patients with severe aortic stenosis (AS) across the spectrum of surgical risk. Despite improvements in transcatheter heart valve (THV) technologies and procedural techniques, cardiac conduction disturbances, including high degree atrioventricular block (AVB) requiring permanent pacemaker (PPM) implantation and new-onset left bundle branch block (LBBB), remain frequent complications. TAVR-related conduction disturbances occur due to injury to the conduction system from interactions with interventional equipment and the transcatheter valve stent frame. Risk factors for post-TAVR conduction disturbances have been identified and include clinical characteristics, baseline electrocardiogram findings (right bundle branch block), anatomic factors, and potentially modifiable procedural factors (type of transcatheter valve, depth of implantation, over-sizing). New-onset LBBB and PPM implantation after TAVR have been shown to be associated with adverse longterm clinical outcomes, including mortality and heart failure hospitalization. These clinical consequences are likely to be of increasing importance as TAVR is utilized in younger and lower risk population. This review provides an updated overview of the literature regarding the incidence, predictors, and clinical outcomes of TAVR-related conduction disturbances, as well as proposed strategies for the management of this frequent clinical challenge.

show abstract

Mortality and major adverse cardiovascular events after transcatheter aortic valve replacement using Edwards valve versus CoreValve: A meta-analysis

Cited by 12 publications

References 37 publications

Comparison of third generation balloon-expandable Edwards Sapien 3 versus self-expandable Evolut R in transcatheter aortic valve implantation: a meta-analysis

Comparison of third generation balloon-expandable Edwards Sapien 3 versus self-expandable Evolut R in transcatheter aortic valve implantation: a meta-analysis

Contemporary transcatheter aortic valve replacement with third‐generation balloon‐expandable versus self‐expanding devices

The incidence and impact of cardiac conduction disturbances after transcatheter aortic valve replacement

Contact Info

Product

Resources

About